Alkeus Pharmaceuticals Announces Presentation of Positive Gildeuretinol Data in Early-Stage Stargardt Patients During the ARVO 2024 Annual Meeting May 5-9
May 01, 2024 09:00 ET
|
Alkeus Pharmaceuticals
Alkeus Pharmaceuticals Announces Presentation of Positive Gildeuretinol Data in Early-Stage Stargardt Patients During the ARVO 2024 Annual Meeting May 5-9
AAVantgarde announces updated NHP data from its Stargardt disease program in a poster presentation at the ARVO 2024 annual meeting
April 24, 2024 02:00 ET
|
AAVantgarde Bio
AAVantgarde announces updated NHP data from its Stargardt disease program in a poster presentation at the ARVO 2024 annual meeting
AAVantgarde presents positive preclinical data in large animal models from its Stargardt disease program in an oral presentation at the ASGCT 2024 annual meeting
April 23, 2024 02:00 ET
|
AAVantgarde Bio
AAVantgarde presents positive preclinical data in large animal models from its Stargardt disease program in an oral presentation at ASGCT 2024
Alkeus Pharmaceuticals Presents Positive Interim Data Showing Gildeuretinol Halted Stargardt Disease Progression
January 10, 2024 06:00 ET
|
Alkeus Pharmaceuticals
All three patients treated for two years or more have remained free of symptoms and disease progression while taking gildeuretinol.TEASE-3 is the first clinical trial in early-stage Stargardt disease,...
AAVantgarde Closes €61 Million Series A Financing to Advance Two Therapeutic Programs into the Clinic
June 06, 2023 08:00 ET
|
AAVantgarde Bio
- Financing led by Atlas Venture and Forbion - Company created, incubated and seed financed by Sofinnova Partners MILAN, Italy, June 06, 2023 (GLOBE NEWSWIRE) -- AAVantgarde Bio (AAVantgarde), a...
Alkeus Announces $150 Million Series B Financing, Supporting Rapid Registration Path for gildeuretinol (ALK-001) in the Treatment of Stargardt Disease
June 05, 2023 06:00 ET
|
Alkeus Pharmaceuticals
CAMBRIDGE, Mass., June 05, 2023 (GLOBE NEWSWIRE) -- Alkeus Pharmaceuticals announced today that it has raised a $150 million Series B financing to support the registration and launch of...
Foundation Fighting Blindness Clinical Research Institute to Launch Natural History Study for Stargardt Disease to Help Prepare for Clinical Trials
March 13, 2013 15:07 ET
|
Foundation Fighting Blindness
COLUMBIA, Md., March 13, 2013 (GLOBE NEWSWIRE) -- The Foundation Fighting Blindness Clinical Research Institute is launching a natural history study of people affected by Stargardt disease, a genetic...